PCN254 AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
May 1, 2019, 00:00
10.1016/j.jval.2019.04.375
https://www.valueinhealthjournal.com/article/S1098-3015(19)30567-4/fulltext
Title :
PCN254 AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)30567-4&doi=10.1016/j.jval.2019.04.375
First page :
Section Title :
Open access? :
No
Section Order :
10024